Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming’s technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company’s commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.

Employee Rating

5.0
TypePublic
HQLeiden, NL
Founded1988
Size (employees)94 (est)
Websitepharming.com
Pharming Group was founded in 1988 and is headquartered in Leiden, NL
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Pharming Group Office Locations

Pharming Group has an office in Leiden
Leiden, (HQ)
24 Darwinweg
Show all (1)
Report incorrect company information

Pharming Group News and Updates

Global Hereditary Angioedema Therapeutics Market 2018-2022: Market to Grow at a CAGR of 8.94% with BioCryst Pharmaceuticals, Cipla, CSL, Pharming Group & Shire Dominating

DUBLIN, Sept. 25, 2018 /PRNewswire/ -- The "Global Hereditary Angioedema Therapeutics Market 2018-2022" report has been added to ResearchAndMarkets.com's offering. The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022. The report...
Report incorrect company information

Pharming Group Blogs

Pharming reports favourable conclusion from first investigator-initiated direct comparative real-world study of acute hereditary angioedema therapies

Treatment with recombinant therapy RUCONEST® and plasma-derived C1 treatments requires significantly less re-dosing than icatibant (Firazyr®) to resolve HAE attacks Leiden, The Netherlands, 7 December 2018: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today acknowled…

Pharming Group reports interim financial results for the first nine months of 2018

Compared with the first nine months of 2017 (on a like-for-like basis): Product revenues up 74% to €97.7 million, operating profit up 144% to €31.0 million, net profit up 131% to 11.7 million Compared with the last quarter ended 30 June 2018: Product revenues up 30% to €38.6 million, operating profi…

Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy

Primary Endpoint was met, with rhC1INH treatment reducing neutrophil gelatinase-associated lipocalin (NGAL), a widely recognized marker of acute renal damage Leiden, The Netherlands, 17 October 2018: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today announced positi…

Pharming ontvangt Complete Response Letter van FDA

Verzoek tot aanvullende klinische onderzoeksgegevens voor profylaxe van erfelijk agio-oedeem Leiden, 19 September 2018, Pharming Group N.V. (“Pharming” of “de Onderneming”) (Euronext Amsterdam: PHARM) maakt bekend dat het een zogeheten Complete Response Letter (CRL) van de Amerikaanse Food and Drug …

Pharming Receives Complete Response Letter from FDA

Additional clinical trial data for prophylaxis of HAE requested Leiden, The Netherlands, 19 September 2018, Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA)…

Pharming geeft aandelen uit door uitoefening van opties door management

Uitoefening van 6.240.000 managementopties, waardoor het belang van het management in Pharming met 26% is toegenomen Leiden, 30 juli 2018: Pharming Group N.V. (“Pharming” of “de Onderneming”) (Euronext Amsterdam: PHARM) maakt bekend dat het een totaal van 6.240.000 nieuwe aandelen heeft uitgegeven n…
Show more

Pharming Group Company Life and Culture

Report incorrect company information

Pharming Group Frequently Asked Questions

  • When was Pharming Group founded?

    Pharming Group was founded in 1988.

  • How many employees does Pharming Group have?

    Pharming Group has 94 employees.

  • Who are Pharming Group competitors?

    Competitors of Pharming Group include Keryx Biopharmaceuticals, NovaBay Pharmaceuticals and Chiasma.

  • Where is Pharming Group headquarters?

    Pharming Group headquarters is located at 24 Darwinweg, Leiden.

  • Where are Pharming Group offices?

    Pharming Group has an office in Leiden.

  • How many offices does Pharming Group have?

    Pharming Group has 1 office.